The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder

Although expanding the availability of buprenorphine—a first-line pharmacotherapy for opioid-use disorder (OUD)—has increased the capacity of healthcare systems to offer treatment, starting this medication is fraught with significant barriers. Standard induction regimens require persons with OUD to...

Descripción completa

Detalles Bibliográficos
Autores principales: De Aquino, Joao P., Parida, Suprit, Sofuoglu, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020374/
https://www.ncbi.nlm.nih.gov/pubmed/33818748
http://dx.doi.org/10.1007/s40261-021-01032-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020374/
https://www.ncbi.nlm.nih.gov/pubmed/33818748
http://dx.doi.org/10.1007/s40261-021-01032-7

Ejemplares similares